<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04636229</url>
  </required_header>
  <id_info>
    <org_study_id>19 OA 001 ASA</org_study_id>
    <nct_id>NCT04636229</nct_id>
  </id_info>
  <brief_title>Efficacy of Amniotic Suspension Allograft in Patients With Osteoarthritis of the Knee</brief_title>
  <official_title>A Phase 3 Prospective, Multicenter, Double-blind, Randomized, Placebo-controlled Study to Evaluate the Efficacy of Amniotic Suspension Allograft (ASA) in Patients With Osteoarthritis of the Knee</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Organogenesis</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Premier Research International LLC</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Organogenesis</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is being conducted to evaluate the efficacy and safety of ASA compared to placebo&#xD;
      in the management of osteoarthritis (OA) symptoms of the knee.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a prospective, multicenter, randomized, double-blind, placebo-controlled Phase 3&#xD;
      study of ASA in patients with OA of the knee. Initially, 474 subjects are planned for&#xD;
      inclusion in this study using a group sequential design with two interim analyses and a final&#xD;
      analysis. Sample size re-estimation is planned at the second interim analysis. Based on&#xD;
      conditional power, the maximum sample size may be increased to up to 700 patients. Patients&#xD;
      will be randomly assigned in a 1:1 ratio to receive a single intra-articular (IA) injection&#xD;
      of 2 mL of ASA (plus 2 mL of normal saline) or 4 mL of normal saline.&#xD;
&#xD;
      Patients will be screened after informed consent is obtained. Eligible patients will be&#xD;
      randomized to receive a single IA injection on Day 1. They will have serial assessments of&#xD;
      knee pain, function, and symptoms scores, as well as safety assessments for up to 52 weeks&#xD;
      after administration of the study drug.&#xD;
&#xD;
      The planned sequence and maximum duration of the study periods will be as follows:&#xD;
&#xD;
        -  Screening: 2 weeks&#xD;
&#xD;
        -  Treatment: 1 day&#xD;
&#xD;
        -  Follow-up: 52 weeks&#xD;
&#xD;
      The maximum treatment duration for each patient is 1 day.&#xD;
&#xD;
      The maximum study duration for each patient is 54 weeks.&#xD;
&#xD;
      Efficacy will be assessed via Western Ontario and McMaster Universities Osteoarthritis Index&#xD;
      (WOMAC) and Outcome Measures in Rheumatology-Osteoarthritis Research Society International&#xD;
      (OMERACT-OARSI) responder rates.&#xD;
&#xD;
      Safety will be assessed via monitoring of adverse events (AEs), safety laboratory testing,&#xD;
      vital signs, physical examination, and concomitant medication use.&#xD;
&#xD;
      An independent data monitoring committee (DMC) with a defined charter will review study data&#xD;
      and make preliminary decisions relative to interim analyses.&#xD;
&#xD;
      The assessments that are used in this study are standard, and are generally recognized as&#xD;
      reliable, accurate, and relevant.&#xD;
&#xD;
      No pediatric patients will be included as OA of the knee is an age-related disorder and&#xD;
      rarely occurs in patients under the age of 18 years. The sponsor plans to submit a waiver for&#xD;
      studies in all pediatric age subgroups.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 14, 2020</start_date>
  <completion_date type="Anticipated">December 2023</completion_date>
  <primary_completion_date type="Anticipated">June 2023</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>This is a prospective, multicenter, randomized, double-blind, placebo-controlled study of ASA in patients with OA of the knee. Patients will be randomly assigned in a 1:1 ratio to receive a single IA injection of 2 mL of ASA (plus 2 mL of normal saline) or 4 mL of normal saline.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>All clinic staff who may be involved in making assessments of safety will be blinded to treatment assignment.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>The difference in change from baseline in WOMAC Pain scale at 6 months between ASA- and placebo-treated patients</measure>
    <time_frame>Baseline to Week 26</time_frame>
    <description>The Western Ontario and McMaster Universities (WOMAC®) Osteoarthritis Index is a questionnaire that measures pain, stiffness, and function both independently and collectively, using a Likert 3.1, 5-point scale. The Likert Scale uses the following descriptors for all items: none, mild moderate, severe, and extreme, corresponding to an ordinal scale of 0-4. Higher scores on the WOMAC indicate worse pain, stiffness, and functional limitations.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The difference between changes from baseline for ASA- and placebo- treated patients in WOMAC Function at 6 months</measure>
    <time_frame>Baseline to Week 26</time_frame>
    <description>The Western Ontario and McMaster Universities (WOMAC®) Osteoarthritis Index is a questionnaire that measures pain, stiffness, and function both independently and collectively, using a Likert 3.1, 5-point scale. The Likert Scale uses the following descriptors for all items: none, mild moderate, severe, and extreme, corresponding to an ordinal scale of 0-4. Higher scores on the WOMAC indicate worse pain, stiffness, and functional limitations.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The difference between changes from baseline for ASA- and placebo-treated patients in the OMERACT-OARSI responder rate at 6 months</measure>
    <time_frame>Baseline to Week 26</time_frame>
    <description>Outcome Measures in Rheumatoid Arthritis Clinical Trials - Osteoarthritis Research Society International. (OMERACT-OARSI) Responders are defined as participants with high improvement in pain or function.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The difference between changes from baseline for ASA- and placebo-treated patients in WOMAC Pain at 3 months</measure>
    <time_frame>Baseline to Week 12</time_frame>
    <description>The Western Ontario and McMaster Universities (WOMAC®) Osteoarthritis Index is a questionnaire that measures pain, stiffness, and function both independently and collectively, using a Likert 3.1, 5-point scale. The Likert Scale uses the following descriptors for all items: none, mild moderate, severe, and extreme, corresponding to an ordinal scale of 0-4. Higher scores on the WOMAC indicate worse pain, stiffness, and functional limitations.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The difference between changes from baseline for ASA- and placebo- treated patients in non-inferiority of WOMAC Function at 3 months</measure>
    <time_frame>Baseline to Week 12</time_frame>
    <description>The Western Ontario and McMaster Universities (WOMAC®) Osteoarthritis Index is a questionnaire that measures pain, stiffness, and function both independently and collectively, using a Likert 3.1, 5-point scale. The Likert Scale uses the following descriptors for all items: none, mild moderate, severe, and extreme, corresponding to an ordinal scale of 0-4. Higher scores on the WOMAC indicate worse pain, stiffness, and functional limitations.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The difference between changes from baseline for ASA- and placebo-treated patients in the OMERACT-OARSI responder rate at 3 months</measure>
    <time_frame>Baseline to Week 12</time_frame>
    <description>Outcome Measures in Rheumatoid Arthritis Clinical Trials - Osteoarthritis Research Society International. (OMERACT-OARSI) Responders are defined as participants with high improvement in pain or function.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The difference between changes from baseline for ASA- and placebo-treated patients in the WOMAC Total at 6 months</measure>
    <time_frame>Baseline to Week 26</time_frame>
    <description>The Western Ontario and McMaster Universities (WOMAC®) Osteoarthritis Index is a questionnaire that measures pain, stiffness, and function both independently and collectively, using a Likert 3.1, 5-point scale. The Likert Scale uses the following descriptors for all items: none, mild moderate, severe, and extreme, corresponding to an ordinal scale of 0-4. Higher scores on the WOMAC indicate worse pain, stiffness, and functional limitations.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The difference between ASA- and placebo-treated patients in the WOMAC Stiffness at 6 months</measure>
    <time_frame>Baseline to Week 26</time_frame>
    <description>The Western Ontario and McMaster Universities (WOMAC®) Osteoarthritis Index is a questionnaire that measures pain, stiffness, and function both independently and collectively, using a Likert 3.1, 5-point scale. The Likert Scale uses the following descriptors for all items: none, mild moderate, severe, and extreme, corresponding to an ordinal scale of 0-4. Higher scores on the WOMAC indicate worse pain, stiffness, and functional limitations.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The difference between changes from baseline for ASA- and placebo- treated patients in the WOMAC Total at 3 months</measure>
    <time_frame>Baseline to Week 12</time_frame>
    <description>The Western Ontario and McMaster Universities (WOMAC®) Osteoarthritis Index is a questionnaire that measures pain, stiffness, and function both independently and collectively, using a Likert 3.1, 5-point scale. The Likert Scale uses the following descriptors for all items: none, mild moderate, severe, and extreme, corresponding to an ordinal scale of 0-4. Higher scores on the WOMAC indicate worse pain, stiffness, and functional limitations.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The difference between changes from baseline for ASA- and placebo-treated patients in the WOMAC Stiffness at 3 months</measure>
    <time_frame>Baseline to Week 12</time_frame>
    <description>The Western Ontario and McMaster Universities (WOMAC®) Osteoarthritis Index is a questionnaire that measures pain, stiffness, and function both independently and collectively, using a Likert 3.1, 5-point scale. The Likert Scale uses the following descriptors for all items: none, mild moderate, severe, and extreme, corresponding to an ordinal scale of 0-4. Higher scores on the WOMAC indicate worse pain, stiffness, and functional limitations.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of adverse events (AEs)</measure>
    <time_frame>Baseline to Week 52</time_frame>
    <description>An AE is any untoward medical occurrence in a clinical study patient administered a medicinal (investigational or non-investigational) product. An AE does not necessarily have a causal relationship with the treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal finding), symptom, or disease temporally associated with the use of a medicinal (investigational or non-investigational) product, whether or not related to that medicinal (investigational or non-investigational) product.&#xD;
This includes any occurrence that is new in onset or aggravated in severity or frequency from the baseline condition, or abnormal result of diagnostic procedures, including clinical laboratory test abnormalities.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">474</enrollment>
  <condition>Knee Osteoarthritis</condition>
  <arm_group>
    <arm_group_label>ASA</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants receive a single IA injection of 2 mL of ASA (plus 2 mL of normal saline)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants receive a single IA injection of 4 mL of normal saline</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Amniotic Suspension Allograft</intervention_name>
    <description>This investigational product is a cryopreserved product derived from human amnion and cells from the amniotic fluid.</description>
    <arm_group_label>ASA</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Matching placebo is 0.9% normal saline: 4 mL to be injected IA.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Males or females 18 years of age or older&#xD;
&#xD;
          2. Diagnosis of OA of the knee by a combination of clinical and radiographic findings&#xD;
&#xD;
          3. OA of the knee with Kellgren and Lawrence radiographic classification (Grade 2-4&#xD;
             inclusive) confirmed by posterior-anterior, weight-bearing, fixed flexion radiography&#xD;
             with 10° caudal beam angulation. A specially designed positioning frame will be used&#xD;
             to standardize the positioning for image acquisition.&#xD;
&#xD;
          4. Patients who have failed to adequately respond for at least 6 months to at least 2 OA&#xD;
             therapies that include conservative, non-pharmacological therapy and simple analgesics&#xD;
             (e.g., acetaminophen); nonsteroidal anti-inflammatory drugs (NSAIDS); avoidance of&#xD;
             activities that cause joint pain; exercise; weight loss; physical therapy; and removal&#xD;
             of excess fluid from the knee&#xD;
&#xD;
          5. Overall pain score over the previous 7 days of 11 or more on the WOMAC Pain scale.&#xD;
&#xD;
          6. Body mass index (BMI) &lt; 40 kg/m²&#xD;
&#xD;
          7. If female, must be postmenopausal (for at least 2 years), surgically sterilized&#xD;
             (bilateral tubal ligation, bilateral oophorectomy, or hysterectomy), sexually&#xD;
             abstinent, or willing and able to use 2 methods of contraception from Day 1 through 12&#xD;
             months after treatment&#xD;
&#xD;
          8. Males who are not surgically sterile (vasectomy) for at least 6 months prior to&#xD;
             screening must confirm their willingness to use adequate methods of contraception from&#xD;
             Day 1 through 12 months after treatment&#xD;
&#xD;
          9. Willing to agree not to use illicit drugs during the study, and to have illicit drug&#xD;
             testing at screening and at later time points, if illicit drug use is suspected during&#xD;
             the study&#xD;
&#xD;
         10. Able to comply with study requirements and complete the full sequence of&#xD;
             protocol-related procedures and evaluations, including post-hospitalization,&#xD;
             out-patient, and follow-up visits&#xD;
&#xD;
         11. Able to understand and provide written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Use of pain medication (including NSAIDs and cannabidiol [CBD] oil) less than 15 days&#xD;
             before treatment (acetaminophen allowed)&#xD;
&#xD;
          2. Regular use of anticoagulants&#xD;
&#xD;
          3. Symptoms of locking, intermittent block to range of motion, or loose body sensation&#xD;
             that could indicate meniscal displacement or an IA loose body&#xD;
&#xD;
          4. Corticosteroid injection into the index knee within 3 months prior to screening&#xD;
&#xD;
          5. Viscosupplement (e.g., hyaluronic acid [HA]) injection, platelet-rich plasma&#xD;
             injection, bone marrow aspirate (BMA) or bone marrow aspiration concentrate (BMAC),&#xD;
             placental-derived tissue/cells, adipose tissue, or any other autologous or allogeneic&#xD;
             product into the index knee within 6 months prior to screening&#xD;
&#xD;
          6. Patients with known hypersensitivity reactions to ASA or any of its constituents&#xD;
             (e.g., HA, dimethyl sulfoxide [DMSO])&#xD;
&#xD;
          7. Knee surgery on the index knee within 12 months prior to screening and/or planned knee&#xD;
             surgery during the study&#xD;
&#xD;
          8. Knee surgery on the contralateral knee within 6 months prior to screening and/or&#xD;
             planned knee surgery during the study&#xD;
&#xD;
          9. Acute index knee trauma within 3 months prior to screening&#xD;
&#xD;
         10. Knee effusion requiring aspiration of the index or contralateral knee within 3 months&#xD;
             prior to screening&#xD;
&#xD;
         11. Contralateral knee pain ≥ 4 on the WOMAC Pain scale on most days during the past week.&#xD;
&#xD;
         12. Current therapy with any immunosuppressive therapy, including corticosteroids (&gt; 5&#xD;
             mg/day of prednisone)&#xD;
&#xD;
         13. Clinically significant findings on the screening laboratory tests or physical&#xD;
             examination that are not specific to OA of the knee and may interfere with study&#xD;
             conduct or interpretation of data or increase patient risk&#xD;
&#xD;
         14. Clinically significant intercurrent illness, medical condition, non-knee pain, or&#xD;
             medical history (including neurological or mental illness, human immunodeficiency&#xD;
             virus, fibromyalgia, complex regional pain syndrome, or any active infection,&#xD;
             including hepatitis B or C) that could jeopardize the patient safety, limit&#xD;
             participation, or compromise interpretation of data derived from the patient&#xD;
&#xD;
         15. Active alcohol or substance use disorder, or any other reason that would make it&#xD;
             unlikely for the patient to comply with study procedures&#xD;
&#xD;
         16. Females who are pregnant (positive pregnancy test at screening or prior to treatment)&#xD;
             or lactating&#xD;
&#xD;
         17. Participation in another clinical trial within the 30 days (or 5 half-lives of the&#xD;
             investigational compound, whichever is longer) before screening&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Brett Madden</last_name>
    <phone>(781) 615-1876</phone>
    <email>bmadden@organo.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Christine McLennan</last_name>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Central Research Associates</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35205</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shannon Helton</last_name>
      <phone>205-327-1077</phone>
      <email>shannon@centraltrials.com</email>
    </contact>
    <investigator>
      <last_name>Kenneth Jaffe, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Alabama Clinical Therapeutics</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35235</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jill Andringa, RN</last_name>
      <phone>205-833-2228</phone>
      <email>jill.andringa@actstudy.net</email>
    </contact>
    <investigator>
      <last_name>Bradly Goodman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>AMR Mobile</name>
      <address>
        <city>Mobile</city>
        <state>Alabama</state>
        <zip>36608</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lauren Garner</last_name>
      <phone>251-414-1984</phone>
    </contact>
    <investigator>
      <last_name>Russell Hudgens, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Arizona Arthritis &amp; Rheumatology Research</name>
      <address>
        <city>Glendale</city>
        <state>Arizona</state>
        <zip>85306</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gloria Santimaw</last_name>
      <phone>602-386-4970</phone>
      <email>gloria.santimaw@azarthritis.com</email>
    </contact>
    <investigator>
      <last_name>John Tesser, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fiel Family &amp; Sports Medicine/ CCT Research</name>
      <address>
        <city>Tempe</city>
        <state>Arizona</state>
        <zip>85283</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mathew Maasberg</last_name>
      <phone>480-630-7120</phone>
    </contact>
    <investigator>
      <last_name>Thomas Fiel</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Arizona Arthritis &amp; Rheumatology Research</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85704</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Debra Burge</last_name>
      <phone>520-332-2952</phone>
      <email>Debra.bruge@azarthritis.com</email>
    </contact>
    <investigator>
      <last_name>Jeffrey Loomer, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tri West Research Associates</name>
      <address>
        <city>El Cajon</city>
        <state>California</state>
        <zip>92020</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jenny Hilton</last_name>
      <phone>619-334-4735</phone>
      <email>jhilton@triwestresearch.com</email>
    </contact>
    <investigator>
      <last_name>Louis Levy</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Horizon Clinical Research Center</name>
      <address>
        <city>La Mesa</city>
        <state>California</state>
        <zip>91942</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dino Subasic</last_name>
      <phone>619-456-6012</phone>
      <email>dino@horizontrials.com</email>
    </contact>
    <investigator>
      <last_name>Scott Hacker</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Actca, A Member of the Allliance Inc.</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90036</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>ELI DELLACRUZ</last_name>
      <phone>310-289-8242</phone>
    </contact>
    <investigator>
      <last_name>Lydie Hazan</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of California at Los Angeles</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dana Levin</last_name>
      <phone>310-825-6095</phone>
    </contact>
    <investigator>
      <last_name>Kristofer Jones</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of California at Davis</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95186</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chancey Sweeney</last_name>
    </contact>
    <investigator>
      <last_name>Cassandra Lee</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Bone and Joint Institute</name>
      <address>
        <city>Hartford</city>
        <state>Connecticut</state>
        <zip>06106</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bethany Samperi</last_name>
      <phone>860-972-5978</phone>
      <email>bethany.samperi@hhchealth.org</email>
    </contact>
    <investigator>
      <last_name>Carl Nissen</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>AARDS Research, Inc.</name>
      <address>
        <city>Aventura</city>
        <state>Florida</state>
        <zip>33180</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Odence DeLaRosa</last_name>
      <phone>305-932-4162</phone>
      <email>odcherub1@aol.com</email>
    </contact>
    <investigator>
      <last_name>Norman Gaylis</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Pinnacle Trials, Inc.</name>
      <address>
        <city>Stockbridge</city>
        <state>Georgia</state>
        <zip>30281</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Robert Robbins</last_name>
      <phone>404-929-6774</phone>
      <email>robert.robbins@trypinnacle.com</email>
    </contact>
    <investigator>
      <last_name>Francisco Chevres</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Chicago Clinical Research Institute Inc</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60607</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Saad Syed</last_name>
      <phone>312-823-6800</phone>
      <email>Ssyed@ccrii.us</email>
    </contact>
    <investigator>
      <last_name>Dennis Levinson</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rush University Medical Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Kavita Ahuja</last_name>
      <phone>224-229-2988</phone>
      <email>kavita.ahuja@rushortho.com</email>
    </contact>
    <investigator>
      <last_name>Adam Yanke</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Affinity Health</name>
      <address>
        <city>Oak Brook</city>
        <state>Illinois</state>
        <zip>60523</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lorena Watkins</last_name>
      <phone>630-931-3496</phone>
      <email>lwatkins@affinityhealthcorp.com</email>
    </contact>
    <investigator>
      <last_name>Hythem Shadid</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>OrthoIndy</name>
      <address>
        <city>Greenwood</city>
        <state>Indiana</state>
        <zip>46143</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vicki Miller</last_name>
      <phone>317-884-5230</phone>
      <email>vsmiller@orthoindy.com</email>
    </contact>
    <investigator>
      <last_name>Jack Farr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sinai Hospital of Baltimore</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Taj Andrews</last_name>
      <phone>410-601-9592</phone>
    </contact>
    <investigator>
      <last_name>Michael Mont</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Klein &amp; Associates, MD, PA</name>
      <address>
        <city>Hagerstown</city>
        <state>Maryland</state>
        <zip>21740</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Richard Robinson</last_name>
      <phone>301-791-6680</phone>
      <phone_ext>1137</phone_ext>
      <email>rrobinson@rheumdocs.com</email>
    </contact>
    <investigator>
      <last_name>Steven Klein</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tufts Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02111</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Vivian Deng</last_name>
      <phone>617-636-7438</phone>
      <email>vdeng@tuftsmedicalcenter.org</email>
    </contact>
    <investigator>
      <last_name>Steven Vlad</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Methodist Physicians Clinic/ CCT Researc</name>
      <address>
        <city>Fremont</city>
        <state>Nebraska</state>
        <zip>68025</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Renee Hochstein</last_name>
      <phone>402-704-7950</phone>
    </contact>
    <investigator>
      <last_name>Thomas Wolf</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Physician Research Collaboration</name>
      <address>
        <city>Lincoln</city>
        <state>Nebraska</state>
        <zip>68516</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amy Marshall</last_name>
      <phone>402-420-1212</phone>
      <email>amy.johnson@prc.us.com</email>
    </contact>
    <investigator>
      <last_name>Melvin Churchill</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>NYU Langone Health</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Efrain DeJesus</last_name>
      <phone>646-831-8314</phone>
    </contact>
    <investigator>
      <last_name>Eric Strauss</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital for Special Surgery</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>COnnor Fletcher</last_name>
      <phone>917-260-3677</phone>
      <email>fletcherc@hss.edu</email>
    </contact>
    <investigator>
      <last_name>Andreas Gomoll</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>M3 Emerging Medical Research, LLC</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27704</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sharnee Graham</last_name>
      <phone>919-281-1784</phone>
      <email>sgraham@wakeresearch.com</email>
    </contact>
    <investigator>
      <last_name>William Silver</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>M3 Emerging Medical Research, LLC</name>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <zip>27612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hannah Marfia</last_name>
      <phone>919-281-1776</phone>
      <email>hmarfia@wakereasearch.com</email>
    </contact>
    <investigator>
      <last_name>John Solic</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Orthopedics Center</name>
      <address>
        <city>Altoona</city>
        <state>Pennsylvania</state>
        <zip>16602</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Robin Stern</last_name>
    </contact>
    <investigator>
      <last_name>Christopher McClellan</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Orthopedic Center</name>
      <address>
        <city>State College</city>
        <state>Pennsylvania</state>
        <zip>16801</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sue Jepson</last_name>
    </contact>
    <investigator>
      <last_name>Thomas Ellis</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>PCPMG Clinical Research Unit, LLC</name>
      <address>
        <city>Greenville</city>
        <state>South Carolina</state>
        <zip>29501</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Robyn Mathis</last_name>
      <phone>864-269-4416</phone>
      <phone_ext>2132</phone_ext>
      <email>Rmathis@pcpmg.com</email>
    </contact>
    <investigator>
      <last_name>Eric Loudermilk</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Coastal Carolina Research Center</name>
      <address>
        <city>North Charleston</city>
        <state>South Carolina</state>
        <zip>29406</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nikki Shebelskie</last_name>
      <phone>843-856-3784</phone>
      <email>nshelbelskie@coastalcarolinaresearch.com</email>
    </contact>
    <investigator>
      <last_name>Shailesh Patel</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Futuro Clinical Trials</name>
      <address>
        <city>McAllen</city>
        <state>Texas</state>
        <zip>78501</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jessica Rodriguez</last_name>
      <phone>956-534-6433</phone>
      <email>jrodriguezcffc@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Joseph Caporusso</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Spectrum Medical, Inc</name>
      <address>
        <city>Danville</city>
        <state>Virginia</state>
        <zip>24541</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>April Marshall</last_name>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://pubmed.ncbi.nlm.nih.gov/31533151/</url>
    <description>Farr J, et al. A randomized controlled single-blind study demonstrating superiority of ASA injection over hyaluronic acid and saline control for modification of knee OA symptoms. J Knee Surg. 2019; https://doi.org/10.1055/s-0039-1696672.</description>
  </link>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>November 5, 2020</study_first_submitted>
  <study_first_submitted_qc>November 18, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 19, 2020</study_first_posted>
  <last_update_submitted>November 1, 2021</last_update_submitted>
  <last_update_submitted_qc>November 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 3, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Osteoarthritis</keyword>
  <keyword>Knee</keyword>
  <keyword>Arthritis</keyword>
  <keyword>Joint Diseases</keyword>
  <keyword>Musculoskeletal Diseases</keyword>
  <keyword>Rheumatic Diseases</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoarthritis</mesh_term>
    <mesh_term>Osteoarthritis, Knee</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

